H

Hightower Clinical | Oklahoma City, OK

Research site
(Unclaimed)
Location
13924 Quail Pointe Drive Suite B, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Risankizumab
Ozanimod
Upadacitinib
ABT-494
ABX464
Enzalutamide
Eptinezumab
Ustekinumab
Inavolisib
Trastuzumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

22 of 40 total trials

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Met...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: Abiraterone with Prednisone or Enzalutamide
Drug: 177Lu-PSMA-I&T
Locations recently updated

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Other: Placebo
Drug: Ozanimod

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with p...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Drug: Palbociclib
Drug: Giredestrant

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod
Locations recently updated

This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-ce...

Enrolling
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts A-C)
Drug: Mosunetuzumab (Cohorts D-E)

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this stu...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: TAK-788
Locations recently updated

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Ph...

Enrolling
Locally Advanced or Metastatic Breast Cancer
Drug: LHRH Agonist
Drug: Phesgo
Locations recently updated

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcuta...

Enrolling
Metastatic Breast Cancer
Drug: Inavolisib
Drug: Optional Endocrine Therapy of Investigator's Choice

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as mainten...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valv...

Enrolling
Atrial Fibrillation
Stroke
Drug: Non-Vitamin K Oral Antagonists
Device: Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Lead...

Active, not recruiting
Bradycardia
Cardiac Rhythm Disorder
Device: Aveir DR Leadless Pacemaker System

A 4 month growth monitoring study of healthy term infants fed iron fortified infant formula. Infants will be fed ad-libitum for 16 weeks and growth w...

Enrolling
Infant Development
Other: Infant Formula

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to se...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: Efavaleukin alfa
Locations recently updated

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Risankizumab
Drug: Ustekinumab

The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderat...

Enrolling
Ulcerative Colitis
Drug: Tilpisertib Fosmecarbil
Drug: Placebo

Trial sponsors

AbbVie logo
Abbott logo
Celgene logo
Pfizer logo
Roche logo
A
Gilead Sciences logo
Amgen logo
Aussie Bubs logo
B. Braun logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems